Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42,171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors.
Lipton JH, Bryden P, Sidhu MK, Huang H, McGarry LJ, Lustgarten S, Mealing S, Woods B, Whelan J, Hawkins N. Lipton JH, et al. Among authors: huang h. Leuk Res. 2015 Jan;39(1):58-64. doi: 10.1016/j.leukres.2014.10.005. Epub 2014 Nov 1. Leuk Res. 2015. PMID: 25466286 Review.
Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.
Jabbour E, DerSarkissian M, Duh MS, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, O'Brien S, Ravandi F, Kantarjian HM. Jabbour E, et al. Among authors: huang h. Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):257-265. doi: 10.1016/j.clml.2018.02.010. Epub 2018 Feb 17. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29519619
Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.
Levy MY, McGarry LJ, Huang H, Lustgarten S, Chiroli S, Iannazzo S. Levy MY, et al. Among authors: huang h. Curr Med Res Opin. 2019 Mar;35(3):479-487. doi: 10.1080/03007995.2018.1510225. Epub 2018 Aug 24. Curr Med Res Opin. 2019. PMID: 30086654
Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd.
Chari A, Richardson PG, Romanus D, Dimopoulos MA, Sonneveld P, Terpos E, Hajek R, Raju A, Palumbo A, Cain LE, Blazer M, Huang H, Farrelly E, Ailawadhi S. Chari A, et al. Among authors: huang h. Expert Rev Hematol. 2020 Apr;13(4):421-433. doi: 10.1080/17474086.2020.1729734. Epub 2020 Mar 9. Expert Rev Hematol. 2020. PMID: 32148109 Free article.
Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.
Kawata AK, Lenderking WR, Eseyin OR, Kerstein D, Huang J, Huang H, Zhang P, Lin HM. Kawata AK, et al. Among authors: huang h, huang j. J Med Econ. 2019 Sep;22(9):924-935. doi: 10.1080/13696998.2019.1624080. Epub 2019 Jun 25. J Med Econ. 2019. PMID: 31125274 Free article. Clinical Trial.
Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma.
Chari A, Romanus D, Palumbo A, Blazer M, Farrelly E, Raju A, Huang H, Richardson P. Chari A, et al. Among authors: huang h. Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):8-17.e16. doi: 10.1016/j.clml.2019.09.625. Epub 2019 Oct 10. Clin Lymphoma Myeloma Leuk. 2020. PMID: 31722839 Free article.
42,171 results
You have reached the last available page of results. Please see the User Guide for more information.